SPN-821

Phase 2Small molecule

Supernus Pharmaceuticals, Inc.

SPN-821 is one of 44 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

Major Depressive DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 2

Risperdal

WWim Janssens

Phase 3

2 3

ALKS 37

AAlkermes, Inc.

Phase 3

6 4

Desvenlafaxine SR

Pfizer

Phase 3

13 5

Brenipatide

Eli Lilly

Phase 3

—6

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 7

Seltorexant

Johnson & Johnson

Phase 3

5 8

Aticaprant

Johnson & Johnson

Phase 3

4 9

NBI-1065845

Neurocrine Biosciences

Phase 3

6 10

MM120

DDefinium Therapeutics US, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Major Depressive Disorder

NCT07226661

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Recruiting· Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.·Phase 2·NCT07226661·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SPN-821. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPN-821 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPN-821. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Supernus Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Supernus Pharmaceuticals, Inc.

SPN-821

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News